proteinase free heparitinase i  (Millipore)


Bioz Verified Symbol Millipore is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 85

    Structured Review

    Millipore proteinase free heparitinase i
    TG2 extracellular location depends on the HS chains of HSPGs. Kidney cryosections were treated with 50 mU/ml protease-free <t>heparitinase</t> I (Hep-I) for 2 hours at 37°C. Extracellular TG2 was immunolabeled using mouse anti-TG2 IA12 antibody followed
    Proteinase Free Heparitinase I, supplied by Millipore, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/proteinase free heparitinase i/product/Millipore
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    proteinase free heparitinase i - by Bioz Stars, 2020-09
    85/100 stars

    Images

    1) Product Images from "Syndecan-4 Knockout Leads to Reduced Extracellular Transglutaminase-2 and Protects against Tubulointerstitial Fibrosis"

    Article Title: Syndecan-4 Knockout Leads to Reduced Extracellular Transglutaminase-2 and Protects against Tubulointerstitial Fibrosis

    Journal: Journal of the American Society of Nephrology : JASN

    doi: 10.1681/ASN.2013050563

    TG2 extracellular location depends on the HS chains of HSPGs. Kidney cryosections were treated with 50 mU/ml protease-free heparitinase I (Hep-I) for 2 hours at 37°C. Extracellular TG2 was immunolabeled using mouse anti-TG2 IA12 antibody followed
    Figure Legend Snippet: TG2 extracellular location depends on the HS chains of HSPGs. Kidney cryosections were treated with 50 mU/ml protease-free heparitinase I (Hep-I) for 2 hours at 37°C. Extracellular TG2 was immunolabeled using mouse anti-TG2 IA12 antibody followed

    Techniques Used: Immunolabeling

    Related Articles

    other:

    Article Title:
    Article Snippet: Proteinase-free heparitinase I (EC 4.2.2.8) (Sigma-Aldrich) was used to digest the side chains of HSPG.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 85
    Millipore heparinase iii wnt5a serum free media
    Heparin competes with <t>Wnt5A</t> binding of HS, and removal of HS decreases motility in melanoma cell lines. Cells were treated with increasing doses of heparin, and the medium of the cells was examined for Wnt5A release. A , in the presence of heparin, Wnt5A accumulates in the medium. The addition of rWnt5A to cells in the absence of heparin results in its rapid uptake and internalization, but in the presence of heparin, rWnt5A just accumulates in the medium. B , PKC signaling is affected by high doses of heparin, regardless of whether rWnt5A is added. C , cells were treated with 2 milliunits/ml <t>heparinase</t> <t>III</t> for 24 h and examined for PKC signaling. PKC signaling is decreased upon heparinase III treatment and partially reconstituted upon the addition of rWnt5A. D , representative images of the motility assays using M93-047 cells demonstrating that heparinase III treatment decreased the rate of wound closure. E , graphical representation of UACC903 scratch closure rates demonstrating that rWnt5A addition can overcome heparinase III treatment. F , quantitative extracellular matrix invasion assays also demonstrate that heparinase III treatment decreases the rate of melanoma cell invasion, and this can be restored upon the addition of exogenous Wnt5A to the media of the cells ( n = 3; error bars show S.D.; **, p
    Heparinase Iii Wnt5a Serum Free Media, supplied by Millipore, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/heparinase iii wnt5a serum free media/product/Millipore
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    heparinase iii wnt5a serum free media - by Bioz Stars, 2020-09
    85/100 stars
      Buy from Supplier

    Image Search Results


    Heparin competes with Wnt5A binding of HS, and removal of HS decreases motility in melanoma cell lines. Cells were treated with increasing doses of heparin, and the medium of the cells was examined for Wnt5A release. A , in the presence of heparin, Wnt5A accumulates in the medium. The addition of rWnt5A to cells in the absence of heparin results in its rapid uptake and internalization, but in the presence of heparin, rWnt5A just accumulates in the medium. B , PKC signaling is affected by high doses of heparin, regardless of whether rWnt5A is added. C , cells were treated with 2 milliunits/ml heparinase III for 24 h and examined for PKC signaling. PKC signaling is decreased upon heparinase III treatment and partially reconstituted upon the addition of rWnt5A. D , representative images of the motility assays using M93-047 cells demonstrating that heparinase III treatment decreased the rate of wound closure. E , graphical representation of UACC903 scratch closure rates demonstrating that rWnt5A addition can overcome heparinase III treatment. F , quantitative extracellular matrix invasion assays also demonstrate that heparinase III treatment decreases the rate of melanoma cell invasion, and this can be restored upon the addition of exogenous Wnt5A to the media of the cells ( n = 3; error bars show S.D.; **, p

    Journal: The Journal of Biological Chemistry

    Article Title: Heparan Sulfate Proteoglycan Modulation of Wnt5A Signal Transduction in Metastatic Melanoma Cells *

    doi: 10.1074/jbc.M109.028498

    Figure Lengend Snippet: Heparin competes with Wnt5A binding of HS, and removal of HS decreases motility in melanoma cell lines. Cells were treated with increasing doses of heparin, and the medium of the cells was examined for Wnt5A release. A , in the presence of heparin, Wnt5A accumulates in the medium. The addition of rWnt5A to cells in the absence of heparin results in its rapid uptake and internalization, but in the presence of heparin, rWnt5A just accumulates in the medium. B , PKC signaling is affected by high doses of heparin, regardless of whether rWnt5A is added. C , cells were treated with 2 milliunits/ml heparinase III for 24 h and examined for PKC signaling. PKC signaling is decreased upon heparinase III treatment and partially reconstituted upon the addition of rWnt5A. D , representative images of the motility assays using M93-047 cells demonstrating that heparinase III treatment decreased the rate of wound closure. E , graphical representation of UACC903 scratch closure rates demonstrating that rWnt5A addition can overcome heparinase III treatment. F , quantitative extracellular matrix invasion assays also demonstrate that heparinase III treatment decreases the rate of melanoma cell invasion, and this can be restored upon the addition of exogenous Wnt5A to the media of the cells ( n = 3; error bars show S.D.; **, p

    Article Snippet: Cells were serum-starved for 2 h and treated with 2 milliunits/ml heparinase III for 24 h and/or rWnt5A or rWnt3A for 16 h. Cells were then seeded at 5 × 105 cells/ml in the heparinase III/Wnt5A serum-free media in the transwell insert of a QCM plate (Millipore, Billerica, MA).

    Techniques: Binding Assay